Association of DR4 (TRAIL-R1) Polymorphisms with Cancer Risk in Caucasians: an Updated Meta-analysis |
Chen, Wei
(Faculty of Medicine, Kunming University of Science and Technology)
Tang, Wen-Ru (Faculty of Medicine, Kunming University of Science and Technology) Zhang, Ming (Faculty of Life Science and Technology, Kunming University of Science and Technology) Chang, Kwenjen (Faculty of Life Science and Technology, Kunming University of Science and Technology) Wei, Yun-Lin (Faculty of Life Science and Technology, Kunming University of Science and Technology) |
1 | Tastemir-Korkmaz D, Demirhan O, Kuleci S, et al (2013). There is no significant association between death receptor 4 (DR4) gene polymorphisms and lung cancer in Turkish population. Pathol Oncol Res, 19, 779-84. DOI ScienceOn |
2 | Yagita H, Takeda K, Hayakawa Y, et al (2004). TRAIL and its receptors as targets for cancer therapy. Cancer Sci, 95, 777-83. DOI ScienceOn |
3 | Mittal RD, Srivastava P, Mittal T, et al (2011). Association of death receptor 4, Caspase 3 and 5 gene polymorphism with increased risk to bladder cancer in North Indians. EuR J Surg Oncol, 37, 727-33. DOI ScienceOn |
4 | Pan GH, Ni J, Wei YF, et al (1997). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815-8. DOI ScienceOn |
5 | Sprick MR, Weigand MA, Rieser E, et al (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 12, 599-609. DOI ScienceOn |
6 | Ulybina YM, Kuligina ES, Mitiushkina NV, et al (2009). Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett, 278, 183-91. DOI ScienceOn |
7 | Wajant H, Pfizenmaier K, Scheurich P (2002). TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis, 7, 449-59. DOI ScienceOn |
8 | Wolf S, Mertens D, Pscherer A, et al (2006). Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer, 118, 1831-5. DOI ScienceOn |
9 | Koornstra JJ, Kleibeuker JH, Van Geelen CM, et al (2003). Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonicmucosa, adenomas, and carcinomas. J Pathol, 200, 327-35. DOI ScienceOn |
10 | Hengartner MO (2000). The biochemistry of apoptosis. Nature, 407, 770-6. DOI ScienceOn |
11 | Horaka P, Pilsa D, Roesslera M, et al (2005). Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecol Oncol, 97, 514-8. DOI ScienceOn |
12 | Kim H, Ku SY, Suh CS, et al (2012). Association between endometriosis and polymorphisms in tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels. Arch Gynecol Obstet, 286, 147-53. DOI |
13 | Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48. |
14 | Korner C, Riesner K, Kramer B, et al (2012). TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer, 12, 85. DOI |
15 | Kuraoka K, Matsumura S, Sanada Y, et al (2005). A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep, 14, 465-70. |
16 | MacFarlane M, Ahmad M, Srinivasula SM, et al (1997). Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem, 272, 25417-20. DOI ScienceOn |
17 | Martinez-Ferrandisa JI, Rodriguez-Lovcvpez R, Milnec RL, et al (2007). Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomark, 3, 89-93. |
18 | Bouralexis S, Findlay DM, Evdokiou A (2005). Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis, 10, 35-51. DOI |
19 | Chen B, Liu S, Wang XL, et al (2009). TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer, 45, 2598-605. DOI ScienceOn |
20 | DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. DOI ScienceOn |
21 | Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-anaysis detected by a simple, graphical test. BMJ, 315, 629-34. DOI ScienceOn |
22 | Evan GI, Vousden KH (2001). Proliferation, cell cycle, and apoptosis in cancer. Nature, 411, 342-8. DOI ScienceOn |
23 | Frank B, Shanmugam KS, Beckmann L, et al (2006). Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prevent, 15, 2002-5. DOI ScienceOn |
24 | Fernandez V, Jares P, Bea S, et al (2004). Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica, 89, 1322-31. |
25 | Fisher MJ, Virmani AK, Wu L, et al (2001). Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res, 7, 1688-97. |
26 | Frank B, Hemminki K, Shanmugam KS, et al (2005). Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. Carcinogenesis, 26, 1975-7. DOI ScienceOn |
27 | Hazra A, Chamberlain RM, Grossman HB, et al (2003). Death receptor 4 and bladder cancer risk. Cancer Res, 63, 1157-9. |
28 | Pan GH, ORourke K, Chinnaiyan AM, et al (1997). The receptor for the cytotoxic ligand TRAIL. Science, 276, 111-3. DOI |